Endometrial (Uterine) Cancer Clinical Trials

Researchers are seeking the best dose of BMS-986500 to give alone and with other drugs in people with solid tumors. The people in this study have ovarian, endometrial, gastroesophageal, or breast cancer. Their tumors have spread beyond their original locations.

Researchers want to find the best dose of CTIM-76 to treat advanced ovarian or endometrial cancer. The people in this study have ovarian or endometrial cancer that makes a protein called CLDN6. This protein may fuel cancer growth.

DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.

Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:

BNT326 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called HER3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, BNT326 may help slow or stop the growth of your cancer. It is given intravenously (by vein).

Researchers in this study are assessing the drug ACR-368 alone and in combination with increasing doses of low-dose gemcitabine in people with ovarian, endometrial, or urothelial (bladder) cancer that has come back despite prior treatment. ACR-368 works by stopping cancer cells from repairing damage to themselves and their DNA (genes). Gemcitabine damages the DNA inside cancer cells and prevents the cells from multiplying.

Researchers want to see how well datopotamab deruxtecan (Dato-DXd) works alone and with other drugs against cancer. The people in this study have endometrial, ovarian, or urothelial cancer that has metastasized (spread).

Researchers want to see if elacestrant alone or with abemaciclib works well against endometrial cancer. The people in this study have endometrial cancer that has spread or come back. Their cancers have a protein called the estrogen receptor (ER) and they have a normal version of the p53 gene. This gene stops cancer from growing.

Researchers want to see how well ivonescimab works as a treatment for endometrial and cervical cancers. The people in this study have endometrial or cervical cancer that keeps growing after treatment.

Researchers want to see how well raludotatug deruxtecan (R-DXd) works against advanced solid tumors. The people in this study have the following cancers, which have spread despite treatment: